Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
11-50
employees, estimated range
Backers
2
Better Capital, Celesta
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Better Capital 
Celesta Similar startupsby what they do, their industry and backers
We offer the only multi-omics single-cell technology solution that simultaneously detects SNV, CNV, and protein data from the same cell…
At Prellis Biologics, we harness AI and immune diversity to advance next-gen medicines. Discover our EXIS™ platform and bioprinting…
Panome Bio delivers advanced multi-omics services including Next-Generation Metabolomics, Discovery Proteomics, Transcriptomics, and…
Accelerate your research with Pluto Bio. The collaborative platform for multi-omics data management, analysis, and visualization.
Advanced single-cell solutions by Atrandi. Discover high-throughput single-cell technologies for genomics, screening, and biological…
Voaige is an AI research lab translating cognitive and systems neuroscience into computational principles for reasoning, memory, and search…
News
1Cell ERA Newsletter August 2026
The August 2026 edition of the 1Cell.Ai Newsletter explores a critical shift in precision oncology: moving beyond diagnosis by morphology and beyond genomics alone to understand the complete biology of cancer. This issue examines why a single biopsy, muta
Read more
Report
1Cell ERA Newsletter July 2026
The July 2026 edition of the 1Cell.Ai Newsletter explores a pivotal moment in precision oncology, when emerging evidence becomes clinical practice. This issue unpacks the latest NCCN Bladder Cancer guideline update endorsing ctDNA-based minimal residual d
Read more
Report
Catching the Hallmark Fusion: Integrated DNA + RNA Profiling in Adenoid Cystic Carcinoma
A 63-year-old woman with recurrent metastatic Adenoid Cystic Carcinoma (ACC) underwent integrated DNA and RNA molecular profiling after disease progression to better understand the tumour's biology beyond conventional genomic testing. While DNA analysis i
Read more
Report
When Blood Goes Silent: CSF Sequencing Reveals the Drivers Behind Leptomeningeal Relapse
A 64-year-old non-smoker with EGFR-mutant non-small cell lung cancer (NSCLC) who developed leptomeningeal metastasis despite multiple lines of targeted therapy. While conventional plasma testing failed to identify actionable alterations, CSF-based molecul
Read more
Report
From Uncertainty to Diagnosis: Molecular Profiling Resolves a Spindle Cell Neoplasm
A 76-year-old male with a metastatic spindle cell neoplasm presented a significant diagnostic challenge after histology, immunohistochemistry (IHC), and additional investigations failed to distinguish among multiple spindle cell sarcoma subtypes. Using co
Read more
Report
Analytical Validation and Clinical Implementation of a 1080-Gene Comprehensive Genomic Profiling Assay with Integrated Cloud-Based Analysis for Solid Tumor Molecular Oncology
The Problem With Small Panels Precision oncology depends on knowing the full genomic landscape of a patient's tumour. Yet most clinical laboratories continue to rely on gene panels covering only 50 to 100 genes- panels that routinely miss critical hotspot
Read more
Report
1Cell ERA Newsletter June 2026
ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell.Ai June 2026 Edition Newsletter captures why. From landmark trial data reshaping treatment sequencing to a deeper understanding of how tumours evolve resistance in real time, this
Read more
Report
Potential of urine liquid biopsy in detecting of clinically relevant genomic alterations in advanced genitourinary cancers.
When Plasma Can't Find It; Urine Can Plasma-based liquid biopsy has transformed how we detect and monitor cancer genomically. But it has a quiet blind spot: in patients with low circulating tumour DNA burden, clonal evolution, or treatment-related suppres
Read more
Report
1Cell ERA Newsletter May 2026
The fast-moving world of precision oncology demands an operational engine that is just as sophisticated as the science behind it. In the May 2026 edition of the 1Cell.Ai newsletter, CEO Mohan Uttarwar introduces a purposeful organizational transformation.
Read more
Report
Single-Cell Circulating Tumor Cell Genomics Reveals KRAS-Independent Oncogenic Sub-Populations and Longitudinal Clonal Evolution in Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer's Moving Target:- Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers and one of the hardest to treat precisely, because it doesn't stay still. PDAC tumours exhibit profound intratumoral heterogeneity, with mul
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cupertino
United States
Regional office
Collaborate With Us
20380 Town Center Lane, #218 Cupertino, CA 95014,
Foster City
United States
Engineering / R&D
US Laboratory
320, Hatch Drive, Foster City, CA 94404